Paclitaxel 6 mg/ml Concentrate for Solution for Infusion clinical trials
8 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
OPAL Master Protocol: A Phase 1B/2 Multicohort Umbrella Study to Evaluate the Safety and Efficacy of Novel Treatments and/or Combinations of Treatments in Participants with Ovarian Cancer (OPAL) (PR-3000-02-005/213357) Cohort C: Open-label Phase 2, Randomized, Controlled Multicenter Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants with Homologous Recombination- Deficient Stage III/IV Ovarian Cancer
This study looks at new ways to treat advanced ovarian cancer before surgery. It compares a drug called niraparib with standard chemotherapy. Researchers want to see if the new approach is safer and works better for certain types of ovarian cancer.
For: Ovarian NeoplasmsSpain - Ongoing, recruitingTherapeutic confirmatory (Phase III)
The BURAN Study of Buparlisib (AN2025) In Combination with Paclitaxel Compared to Paclitaxel Alone, in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
This study is looking at a new drug called Buparlisib, combined with a standard chemotherapy drug, Paclitaxel. It's for people with a type of head and neck cancer that has come back or spread. Researchers want to see if this combination helps people live longer compared to Paclitaxel alone.
For: Recurrent or metastatic head and neck squamous cell carcinomaGermany · Italy · Hungary - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Global, Randomized, Phase 3, Open-Label Study of REGN2810 (Anti-PD-1 Antibody) versus Platinum-Based Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic PD-L1 + Non-Small Cell Lung Cancer
This study looks at a new drug (REGN2810) compared to standard chemotherapy for advanced non-small cell lung cancer. It aims to see if the new drug helps people live longer and stops cancer from growing, especially for those whose cancer has a specific protein called PD-L1.
For: Non-small Cell Lung CancerCzechia · Poland · Greece - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Two-Part Randomized, Phase 3 Study of Combinations of Cemiplimab (Anti- PD-1 Antibody) and Platinum-based Doublet Chemotherapy in First-line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer
This study is testing new combinations of anti-cancer medicines for people with advanced non-small cell lung cancer. It aims to see if these new approaches can help people live longer and improve their quality of life, compared to standard treatments.
For: Non-small Cell Lung CancerFrance · Poland · Ireland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Platinum- Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression
This study, called MIRASOL, is testing a new drug, Mirvetuximab Soravtansine, against standard chemotherapy for advanced ovarian, peritoneal, or fallopian tube cancers that are resistant to platinum-based treatments and have high folate receptor-alpha.
For: Platinum-Resistant Advanced High-Grade Epithelial Ovarian · Primary Peritoneal · or Fallopian Tube Cancers with High Folate Receptor-Alpha ExpressionFrance - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer
This study compares a new medicine called Sacituzumab Govitecan with standard treatments for advanced bladder cancer that has spread or can't be removed. Researchers want to see if the new medicine helps people live longer and feel better.
For: Locally Advanced or Metastatic Unresectable Urothelial CancerItaly · France · Sweden - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Study of Novel Combination Therapies in Participants With Previously Untreated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status
This study is looking for new treatment combinations for head and neck cancer that has come back or spread. It's a Phase 2 trial, meaning researchers want to see how well these new drug combinations work and if they are safe.
For: Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaItaly · Spain · France - AuthorisedTherapeutic exploratory (Phase II)
A Phase II, Open-Label, Single-Arm, Multicentre Study of Carboplatin, Paclitaxel, and Tislelizumab in Biomarker-Selected Patients with Resectable Locally Advanced Oral Cavity Squamous Cell Carcinoma - PERSEPHONE Trial
This study looks at a new combination of medicines (chemotherapy with a drug called tislelizumab) for people with a certain type of mouth cancer that can be removed with surgery. We want to see how well this combination shrinks the tumour before surgery.
For: Resectable Locally Advanced Oral Cavity Squamous Cell CarcinomaItaly